Mar 02, 2023 Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
Feb 21, 2023 Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Jan 17, 2023 Checkpoint Therapeutics to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference
Jan 04, 2023 Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
Dec 15, 2022 Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Nov 08, 2022 Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
Aug 12, 2022 Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights